MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 597678 | Name: Spantide II

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Spantide II is a tachykinin antagonist.

Chemical Structure

Spantide II
Spantide II
CAS#129176-97-2

Theoretical Analysis

MedKoo Cat#: 597678

Name: Spantide II

CAS#: 129176-97-2

Chemical Formula: C86H104Cl2N18O13

Exact Mass: 1666.7407

Molecular Weight: 1668.79

Elemental Analysis: C, 61.90; H, 6.28; Cl, 4.25; N, 15.11; O, 12.46

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Spantide II;
IUPAC/Chemical Name
(S)-N1-((R)-1-(((S)-1-(((R)-1-(((S)-1-(((S)-1-amino-1-oxohexan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-2-((R)-3-(3,4-dichlorophenyl)-2-((S)-1-((S)-2-((S)-1-(N6-nicotinoyl-D-lysyl)pyrrolidine-2-carboxamido)-3-(pyridin-3-yl)propanoyl)pyrrolidine-2-carboxamido)propanamido)succinamide
InChi Key
VJPWTVLSHIDVRH-XCHUDMFJSA-N
InChi Code
InChI=1S/C86H104Cl2N18O13/c1-4-5-26-64(75(91)108)97-77(110)65(38-50(2)3)98-80(113)68(43-55-48-95-62-27-11-9-23-57(55)62)100-78(111)66(40-51-19-7-6-8-20-51)99-81(114)69(44-56-49-96-63-28-12-10-24-58(56)63)101-82(115)70(45-74(90)107)102-79(112)67(41-52-31-32-59(87)60(88)39-52)103-83(116)73-30-18-37-106(73)86(119)71(42-53-21-15-33-92-46-53)104-84(117)72-29-17-36-105(72)85(118)61(89)25-13-14-35-94-76(109)54-22-16-34-93-47-54/h6-12,15-16,19-24,27-28,31-34,39,46-50,61,64-73,95-96H,4-5,13-14,17-18,25-26,29-30,35-38,40-45,89H2,1-3H3,(H2,90,107)(H2,91,108)(H,94,109)(H,97,110)(H,98,113)(H,99,114)(H,100,111)(H,101,115)(H,102,112)(H,103,116)(H,104,117)/t61-,64+,65+,66+,67-,68-,69-,70+,71+,72+,73+/m1/s1
SMILES Code
CCCC[C@@H](C(N)=O)NC([C@H](CC(C)C)NC([C@@H](CC1=CNC2=C1C=CC=C2)NC([C@H](CC3=CC=CC=C3)NC([C@@H](CC4=CNC5=C4C=CC=C5)NC([C@H](CC(N)=O)NC([C@@H](CC6=CC=C(Cl)C(Cl)=C6)NC([C@H]7N(C([C@H](CC8=CC=CN=C8)NC([C@H]9N(C([C@@H](CCCCNC(C%10=CC=CN=C%10)=O)N)=O)CCC9)=O)=O)CCC7)=O)=O)=O)=O)=O)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,668.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Shah PP, Desai PR, Singh M. Effect of oleic acid modified polymeric bilayered nanoparticles on percutaneous delivery of spantide II and ketoprofen. J Control Release. 2012 Mar 10;158(2):336-45. doi: 10.1016/j.jconrel.2011.11.016. Epub 2011 Nov 21. PubMed PMID: 22134117; PubMed Central PMCID: PMC3294128. 2: Håkanson R, Leander S, Asano N, Feng DM, Folkers K. Spantide II, a novel tachykinin antagonist having high potency and low histamine-releasing effect. Regul Pept. 1990 Oct 29;31(1):75-82. PubMed PMID: 1702895. 3: Kikwai L, Babu RJ, Kanikkannan N, Singh M. Stability and degradation profiles of Spantide II in aqueous solutions. Eur J Pharm Sci. 2006 Feb;27(2-3):158-66. Epub 2005 Nov 2. PubMed PMID: 16266798. 4: Wiesenfeld-Hallin Z, Xu XJ, Kristensson K, Håkanson R, Feng DM, Folkers K. Antinociceptive and substance P antagonistic effects of intrathecally injected spantide II in rat: no signs of motor impairment or neurotoxicity. Regul Pept. 1990 Jun;29(1):1-11. PubMed PMID: 1697080. 5: Wiesenfeld-Hallin Z, Xu XJ, Håkanson R, Feng DM, Folkers K. The specific antagonistic effect of intrathecal spantide II on substance P- and C-fiber conditioning stimulation-induced facilitation of the nociceptive flexor reflex in rat. Brain Res. 1990 Sep 3;526(2):284-90. PubMed PMID: 1701683. 6: Reid MS, Hökfelt T, Herrera-Marschitz M, Håkanson R, Feng DM, Folkers K, Goldstein M, Ungerstedt U. Intranigral substance P stimulation of striatal dopamine release is inhibited by spantide II: a new tachykinin antagonist without apparent neurotoxicity. Brain Res. 1990 Nov 5;532(1-2):175-81. PubMed PMID: 1704289. 7: Kikwai L, Babu RJ, Prado R, Kolot A, Armstrong CA, Ansel JC, Singh M. In vitro and in vivo evaluation of topical formulations of spantide II. AAPS PharmSciTech. 2005 Oct 31;6(4):E565-72. PubMed PMID: 16408858; PubMed Central PMCID: PMC2750604. 8: Kincy-Cain T, Bost KL. Increased susceptibility of mice to Salmonella infection following in vivo treatment with the substance P antagonist, spantide II. J Immunol. 1996 Jul 1;157(1):255-64. PubMed PMID: 8683123. 9: Malendowicz LK, Rebuffat P, Nussdorfer GG. Stimulatory effect of the substance P antagonist spantide-II on aldosterone secretion of dispersed rat zona glomerulosa cells. Endocr Res. 1997 Feb-May;23(1-2):131-9. PubMed PMID: 9187544. 10: Xu XJ, Hao JX, Wiesenfeld-Hallin Z, Håkanson R, Folkers K, Hökfelt T. Spantide II, a novel tachykinin antagonist, and galanin inhibit plasma extravasation induced by antidromic C-fiber stimulation in rat hindpaw. Neuroscience. 1991;42(3):731-7. PubMed PMID: 1720225. 11: Maggi CA, Patacchini R, Feng DM, Folkers K. Activity of spantide I and II at various tachykinin receptors and NK-2 tachykinin receptor subtypes. Eur J Pharmacol. 1991 Jun 18;199(1):127-9. PubMed PMID: 1716573. 12: Kikwai L, Babu RJ, Kanikkannan N, Singh M. Preformulation stability of Spantide II, a promising topical anti-inflammatory agent for the treatment of psoriasis and contact dermatitis. J Pharm Pharmacol. 2004 Jan;56(1):19-25. PubMed PMID: 14979997. 13: Håkanson R, Wang ZY, Folkers K. Comparison of spantide II and CP-96,345 for blockade of tachykinin-evoked contractions of smooth muscle. Biochem Biophys Res Commun. 1991 Jul 15;178(1):297-301. PubMed PMID: 1712587. 14: Babu RJ, Kikwai L, Jaiani LT, Kanikkannan N, Armstrong CA, Ansel JC, Singh M. Percutaneous absorption and anti-inflammatory effect of a substance P receptor antagonist: spantide II. Pharm Res. 2004 Jan;21(1):108-13. PubMed PMID: 14984264. 15: Wang ZY, Feng DM, Wang YL, Tung SR, Wong K, Strichartz GR, Folkers K, Håkanson R. Pharmacological assessment of spantide II analogues. Eur J Pharmacol. 1994 Aug 1;260(2-3):121-8. PubMed PMID: 7527343. 16: Zubrzycka M, Janecka A, Traczyk WZ. Comparison of antagonistic properties of substance P analogs, spantide I, II and III, on evoked tongue jerks in rats. Endocr Regul. 2000 Mar;34(1):13-8. PubMed PMID: 10808247. 17: Blais M, Mottier L, Germain MA, Bellenfant S, Cadau S, Berthod F. Sensory neurons accelerate skin reepithelialization via substance P in an innervated tissue-engineered wound healing model. Tissue Eng Part A. 2014 Aug;20(15-16):2180-8. doi: 10.1089/ten.tea.2013.0535. Epub 2014 Apr 9. PubMed PMID: 24716723; PubMed Central PMCID: PMC4137331. 18: Zochodne DW, Ho LT. Vasa nervorum constriction from substance P and calcitonin gene-related peptide antagonists: sensitivity to phentolamine and nimodipine. Regul Pept. 1993 Sep 22;47(3):285-90. PubMed PMID: 7694327. 19: Shah PP, Desai PR, Channer D, Singh M. Enhanced skin permeation using polyarginine modified nanostructured lipid carriers. J Control Release. 2012 Aug 10;161(3):735-45. doi: 10.1016/j.jconrel.2012.05.011. Epub 2012 May 14. PubMed PMID: 22617521; PubMed Central PMCID: PMC3412947. 20: Marepally S, Boakye CH, Shah PP, Etukala JR, Vemuri A, Singh M. Design, synthesis of novel lipids as chemical permeation enhancers and development of nanoparticle system for transdermal drug delivery. PLoS One. 2013 Dec 12;8(12):e82581. doi: 10.1371/journal.pone.0082581. eCollection 2013. PubMed PMID: 24349315; PubMed Central PMCID: PMC3861410.